{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:31:30Z","timestamp":1782937890670,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) in ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>FCGR3A 158F\/V polymorphisms were identified in 85 ABOi or HLAi KTx recipients who underwent RTx desensitization at our institution between April 2008 and October 2021. We analyzed these polymorphism groups in relation to their preoperative background and incidence of LON, infection, and rejection. In addition, we examined the risk factors for LON development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The following FCGR3A 158F\/V polymorphisms were identified: FF genotype (<jats:italic>n<\/jats:italic>\u2009=\u200945); FV genotype (<jats:italic>n<\/jats:italic>\u2009=\u200936), and VV genotype (<jats:italic>n<\/jats:italic>\u2009=\u20094). LON occurred in 25 out of 85 recipients within 1\u00a0year after KTx, significantly more frequently in patients with the FCGR3A FV\u2009+\u2009VV genotype (17\/40) than in those with the FF genotype (8\/45) (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). A multivariate analysis identified the V-allele as an independent risk factor for LON (OR, 4.03; 95% CI, 1.38\u201411.73, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). However, there were no significant differences in the incidence rates of post-transplant infection and rejection between the FF and FV\u2009+\u2009VV genotypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Recipients with the FCGR3A 158\u00a0V-allele were identified as having a higher risk of developing LON following KTx with RTx desensitization therapy. However, the presence of this V-allele did not affect the safety or efficacy of RTx desensitization before KTx.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10157-024-02610-7","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:07:37Z","timestamp":1736752057000},"page":"681-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy"],"prefix":"10.1007","volume":"29","author":[{"given":"Yuki","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-0981","authenticated-orcid":false,"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"25","key":"2610_CR1","volume":"6","author":"Y Ko","year":"2020","unstructured":"Ko Y, Kim JY, Kim SH, Kim DH, Lim SJ, Shin S, et al. Acute rejection and infectious complications in ABO- and HLA-incompatible kidney transplantations. Ann Transplant. 2020;6(25): e927420.","journal-title":"Ann Transplant"},{"issue":"12","key":"2610_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/tri.12979","volume":"30","author":"Ko EJ, Yu JH, Yang CW, Chung BH, the Korean Organ Transplantation Registry Study Group","year":"2017","unstructured":"Ko EJ, Yu JH, Yang CW, Chung BH, the Korean Organ Transplantation Registry Study Group. Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study. Transpl Int. 2017;30(12):1215\u201325.","journal-title":"Transpl Int"},{"issue":"3","key":"2610_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","volume":"106","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106(3):795\u2013802.","journal-title":"Blood"},{"issue":"1","key":"2610_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/TP.0b013e31821c1e70","volume":"92","author":"FP Hurst","year":"2011","unstructured":"Hurst FP, Belur P, Nee R, Agodoa LY, Patel P, Abbott KC, et al. Poor outcomes associated with neutropenia after kidney transplantation: Analysis of United States renal data system. Transplantation. 2011;92(1):36\u201340.","journal-title":"Transplantation"},{"issue":"3","key":"2610_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","volume":"90","author":"HR Koene","year":"1997","unstructured":"Koene HR, Kleijer M, Algra J, Roos D, Kr EG, Von Dem Borne A, De Haas M. Fc\u03b3RIIIa-158V\/F Polymorphism Influences the Binding of IgG by Natural Killer Cell Fc\u03b3RIIIa Independently of the Fc\u03b3RIIIa-48L\/R\/H Phenotype. Blood. 1997;90(3):1109\u201314.","journal-title":"Blood"},{"issue":"1\u20132","key":"2610_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jim.2005.06.018","volume":"304","author":"JA Bowles","year":"2005","unstructured":"Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005;304(1\u20132):88\u201399.","journal-title":"J Immunol Methods"},{"issue":"5","key":"2610_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1172\/JCI119616","volume":"100","author":"J Wu","year":"1997","unstructured":"Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100(5):1059\u201370.","journal-title":"J Clin Invest"},{"issue":"2","key":"2610_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.2009.25.0274","volume":"28","author":"WK Weng","year":"2010","unstructured":"Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc Receptor Fc\u03b3RIIIa 158 V\/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin\u2019s Lymphoma. JCO. 2010;28(2):279\u201384.","journal-title":"JCO"},{"issue":"10","key":"2610_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/ajh.21818","volume":"85","author":"S Li","year":"2010","unstructured":"Li S, Chen Y, Evens AM, Lee C, Liao H, Yu C, et al. Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor Fc\u03b3RIIIa 158(V\/F) polymorphism. Am J Hematol. 2010;85(10):810\u20132.","journal-title":"Am J Hematol"},{"issue":"1","key":"2610_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-017-1241-0","volume":"19","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova S, Tesfa D, H\u00e4gglund H, Fadeel B, Vedin I, Zignego AL, et al. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. Arthritis Res Ther. 2017;19(1):44.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2610_CR11","doi-asserted-by":"publisher","first-page":"7903","DOI":"10.1038\/s41598-021-86943-3","volume":"11","author":"N Litjens","year":"2021","unstructured":"Litjens N, Peeters A, van Gestel JK, Klepper M, Betjes M. The FCGR3A 158 V\/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection. Sci Rep. 2021;11(1):7903.","journal-title":"Sci Rep"},{"issue":"4","key":"2610_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.humimm.2017.03.006","volume":"78","author":"LK Das","year":"2017","unstructured":"Das LK, Ide K, Tanaka A, Morimoto H, Shimizu S, Tanimine N, et al. Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients. Hum Immunol. 2017;78(4):357\u201362.","journal-title":"Hum Immunol"},{"issue":"3","key":"2610_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","volume":"40","author":"S Brum","year":"2008","unstructured":"Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, et al. Leukopenia in Kidney Transplant Patients With the Association of Valganciclovir and Mycophenolate Mofetil. Transpl Proc. 2008;40(3):752\u20134.","journal-title":"Transpl Proc"},{"issue":"4","key":"2610_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1179\/1607845414Y.0000000188","volume":"20","author":"Y Arai","year":"2015","unstructured":"Arai Y, Yamashita K, Mizugishi K, et al. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology. 2015;20(4):196\u2013202.","journal-title":"Hematology"},{"issue":"2","key":"2610_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trim.2014.06.001","volume":"31","author":"K Kabei","year":"2014","unstructured":"Kabei K, Uchida J, Iwai T, Yamasaki T, Kuwabara N, Naganuma T, et al. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil. Transpl Immunol. 2014;31(2):92\u20137.","journal-title":"Transpl Immunol"},{"issue":"10","key":"2610_CR16","doi-asserted-by":"publisher","first-page":"e13058","DOI":"10.1111\/ctr.13058","volume":"31","author":"TA Mavrakanas","year":"2017","unstructured":"Mavrakanas TA, Fournier MA, Clairoux S, et al. Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes. Clin Transplant. 2017;31(10):e13058.","journal-title":"Clin Transplant"},{"issue":"4","key":"2610_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14583","volume":"36","author":"S Brar","year":"2022","unstructured":"Brar S, Berry R, Raval AD, Tang Y, Vincenti F, Skartsis N. Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia. Clin Transplant. 2022;36(4): e14583.","journal-title":"Clin Transplant"},{"issue":"4","key":"2610_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2307\/2556115","volume":"36","author":"TH Emigh","year":"1980","unstructured":"Emigh TH. A comparison of tests for hardy-weinberg equilibrium. Biometrics. 1980;36(4):627.","journal-title":"Biometrics"},{"issue":"2","key":"2610_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"M Reff","year":"1994","unstructured":"Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435\u201345.","journal-title":"Blood"},{"issue":"4","key":"2610_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4):443\u20136.","journal-title":"Nat Med"},{"issue":"10","key":"2610_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1445-5994.2011.02587.x","volume":"42","author":"C Keane","year":"2012","unstructured":"Keane C, Nourse JP, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, et al. Homozygous FCGR3A -158 V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B -cell lymphoma. Intern Med J. 2012;42(10):1113\u20139.","journal-title":"Intern Med J"},{"issue":"4","key":"2610_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hon.2305","volume":"35","author":"H Ghesqui\u00e8res","year":"2017","unstructured":"Ghesqui\u00e8res H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, et al. FCGR3A \/ 2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematol Oncol. 2017;35(4):447\u201355.","journal-title":"Hematol Oncol"},{"issue":"2\u20133","key":"2610_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.trim.2013.01.003","volume":"28","author":"H Ishida","year":"2013","unstructured":"Ishida H, Inui M, Furusawa M, Tanabe K. Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation \u2014 Single-center study. Transpl Immunol. 2013;28(2\u20133):93\u20139.","journal-title":"Transpl Immunol"},{"issue":"8","key":"2610_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003495-200161080-00016","volume":"61","author":"JK McGavin","year":"2001","unstructured":"McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61(8):1153\u201383.","journal-title":"Drugs"},{"key":"2610_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14227","volume":"5","author":"S Belga","year":"2024","unstructured":"Belga S, Hernandez C, Kabbani D, Cervera C. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease. Transplant Infectious Dis. 2024;5: e14227.","journal-title":"Transplant Infectious Dis"},{"issue":"7","key":"2610_CR26","first-page":"364","volume":"16","author":"MF Pascutti","year":"2016","unstructured":"Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Front Immunol. 2016;16(7):364.","journal-title":"Front Immunol"},{"issue":"11","key":"2610_CR27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1097\/01.tp.0000242139.13197.7f","volume":"82","author":"ME Cooke","year":"2006","unstructured":"Cooke ME, Potena L, Luikart H, Valantine HA. Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients: impact of acute disease versus subclinical infection. Transplantation. 2006;82(11):1419\u201324.","journal-title":"Transplantation"},{"issue":"5","key":"2610_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jinf.2014.07.001","volume":"69","author":"C Mart\u00edn-Gandul","year":"2014","unstructured":"Mart\u00edn-Gandul C, P\u00e9rez-Romero P, Gonz\u00e1lez-Roncero FM, Berdaguer S, G\u00f3mez MA, Lage E, et al. Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients. J Infect. 2014;69(5):500\u20136.","journal-title":"J Infect"},{"issue":"2018","key":"2610_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9429265","volume":"1","author":"MAM Khalil","year":"2018","unstructured":"Khalil MAM, Khalil MAU, Khan TFT, Tan J. Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. J Transplant. 2018;1(2018):1\u201322.","journal-title":"J Transplant"},{"issue":"2","key":"2610_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/ajt.13492","volume":"16","author":"S Shimizu","year":"2016","unstructured":"Shimizu S, Tanaka Y, Tazawa H, Verma S, Onoe T, Ishiyama K, et al. Fc-Gamma Receptor Polymorphisms Predispose Patients to Infectious Complications After Liver Transplantation. Am J Transplant. 2016;16(2):625\u201333.","journal-title":"Am J Transplant"},{"issue":"9","key":"2610_CR31","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/ajt.14710","volume":"18","author":"ML Arnold","year":"2018","unstructured":"Arnold ML, Kainz A, Hidalgo LG, Eskandary F, Kozakowski N, Wahrmann M, et al. Functional Fc-gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant. 2018;18(9):2261\u201373.","journal-title":"Am J Transplant"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02610-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:02:40Z","timestamp":1746288160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02610-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2610"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02610-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB) of Kobe University Hospital (IRB approval number B220142) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The studies were in accordance with the Declaration of Istanbul.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}